Interleukin-8 homologous polypeptides and therapeutic uses thereof

Abstract

The present invention is directed to novel polypeptides having structural homology to IL-8 and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention. Further provided herein are methods for treatment and diagnosis of inflammatory diseases.

1 - 32 . (canceled)  
     
     
         33 . A method of diagnosing an immune related disease in a mammal comprising 
 providing a test sample of tissue cells from said mammal    detecting the presence or absence of a PRO842 polypeptide in said test sample of tissue cells, wherein the presence or absence of the PRO842 polypeptide in said test sample is indicative of the presence of an immune related disease in said mammal.    
     
     
         34 . A method of diagnosing an immune related disease in a mammal comprising 
 providing a test sample of tissue cells from said mammal    contacting an anti-PRO842 antibody with said test sample of tissue cells and    detecting the presence or absence of the formation of a complex between said antibody and said PRO842 polypeptide, wherein formation of said complex indicates the presence of an immune related disease in said mammal from which said test sample of tissue cells were obtained.    
     
     
         35 . The method of  claim 34  wherein said immune related disease is an immune-mediated inflammatory disease.  
     
     
         36 . The method of  claim 34  wherein said immune related disease is a non-immune-mediated inflammatory disease.  
     
     
         37 . The method of  claim 34  wherein said immune related disease is an infectious disease.  
     
     
         38 . The method of  claim 34  wherein said immune related disease is an immunodeficiency disease.  
     
     
         39 . The method of  claim 34  wherein said immune related disease is a neoplasia.  
     
     
         40 . The method of  claim 34  wherein said immune related disease is selected from the group consisting of: systemic lupus erythematosis, rheumatoid arthritis, juvenile chronic arthritis, spondyloarthropathies, systemic sclerosis, idiopathic inflammatory myopathies, Sjögren's syndrome, systemic vasculitis, sarcoidosis, autoimmune hemolytic anemia, autoimmune thrombocytopenia, thyroiditis, diabetes mellitus, immune-mediated renal disease, demyelinating diseases of the central nervous systems, demyelinating diseases of the peripheral nervous system, hepatobiliary diseases, inflammatory bowel disease, gluten-sensitive enteropathy, and Whipple's disease, autoimmune or immune-mediated skin diseases, psoriasis, allergic diseases, immunologic diseases of the ovaries, immunologic diseases of the lung, transplantation associated diseases, viral diseases, AIDS, herpes, bacterial infections, fungal infections, protozoal infections, parasitic infections, infectious diseases, immunodeficiency disease and neoplasia.  
     
     
         41 . The method  claim 40  wherein said idiopathic inflammatory myopathy is selected from the group consisting of dermatomyositis and polymyositis.  
     
     
         42 . The method of  claim 40  wherein said autoimmune hemolytic anemia is selected from the group consisting of immune pancytopenia and paroxysmal nocturnal hemoglobinuria.  
     
     
         43 . The method of  claim 40  wherein said autoimmune thrombocytopenia is selected from the group consisting of idiopathic thrombocytopenic purpura and immune-mediated thrombocytopenia.  
     
     
         44 . The method of  claim 40  wherein said thyroiditis is selected from the group consisting of Grave's disease, Hashimoto's thyroiditis, juvenile lymphocytic thyroiditis and atrophic thyroiditis.  
     
     
         45 . The method of  claim 40  wherein said immune-mediated renal disease is selected from the group consisting of glomerulonephritis and tubulointerstitial nephritis.  
     
     
         46 . The method of  claim 40  wherein said demyelinating disease is selected from the group consisting of multiple sclerosis, idiopathic demyelinating polyneuropathy, Guillain-Barre syndrome, and chronic inflammatory demyelinating polyneuropathy.  
     
     
         47 . The method of  claim 40  wherein said hepatobiliary disease is selected from the group consisting of hepatitis A, hepatitis B, hepatitis C, hepatitis D, hepatitis E, autoimmune chronic active hepatitis, primary biliary cirrhosis, granulomatous hepatitis, and sclerosing cholangitis.  
     
     
         48 . The method of  claim 40  wherein said inflammatory bowel disease is selected from the group consisting of ulcerative colitis and Crohn's disease.  
     
     
         49 . The method of  claim 40  wherein said autoimmune or immune-mediated skin disease is selected from the group consisting of bullous skin diseases, erythema multiforme and contact dermatitis.  
     
     
         50 . The method of  claim 40  wherein said allergic disease is selected from the group consisting of asthma, allergic rhinitis, atopic dermatitis, food hypersensitivity and urticaria.  
     
     
         51 . The method of  claim 40  wherein said allergic disease is selected from the group consisting of eosinophilic pneumonia, idiopathic pulmonary fibrosis and hypersensitivity pneumonitis.  
     
     
         52 . The method of  claim 40  wherein said transplantation associated disease is selected from the group consisting of graft rejection and graft-versus-host-disease.  
     
     
         53 . The method of  claim 40  wherein said immune related disease is lupus erythematosis.  
     
     
         54 . The method  claim 53  wherein said antibody is a monoclonal antibody.  
     
     
         55 . The method of  claim 40  wherein said immune related disease is rheumatoid arthritis.  
     
     
         56 . The method  claim 55  wherein said antibody is a monoclonal antibody.  
     
     
         57 . The method of  claim 40  where in said neoplasia is a breast neoplasia.  
     
     
         58 . The method  claim 57  wherein said antibody is a monoclonal antibody.  
     
     
         59 . The method of  claim 40  wherein the neoplasia is a lung neoplasia.  
     
     
         60 . The method  claim 59  wherein said antibody is a monoclonal antibody.  
     
     
         61 . The method of  claim 40  wherein the neoplasia is a colon neoplasia.  
     
     
         62 . The method  claim 61  wherein said antibody is a monoclonal antibody.  
     
     
         63 . The method of  claim 34  wherein said anti-PRO842 antibody further comprises a detectable label.  
     
     
         64 . The method of  claim 34  wherein said antibody is selected from the group consisting of a monoclonal antibody, a humanized antibody, an antibody fragment, a single-chain antibody and an anti-idiotypic antibody.  
     
     
         65 . The method of  claim 34  wherein said antibody is a monoclonal antibody comprising nonhuman complementary determining region residues and human framework region residues.  
     
     
         66 . The method of  claim 34  wherein said antibody is an agonist antibody.  
     
     
         67 . The method of  claim 34  wherein said antibody is an antagonist antibody.  
     
     
         68 . The method of  claim 34  wherein said antibody is immobilized on a solid support.  
     
     
         69 . The method of  claim 34  wherein said anti-PRO842 antibody is in admixture with a pharmaceutically acceptable carrier.  
     
     
         70 . The method of  claim 34  wherein said detection of the formation of a complex is carried out by a process selected from the group consisting of light microscopy, flow cytometry and flourimetry.